Milind has made over 8 trades of the Spero Therapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of SPRO stock worth $10,150 on 2 December 2016.
The largest trade he's ever made was exercising 216,624 units of Spero Therapeutics Inc stock on 18 August 2014 worth over $665,036. On average, Milind trades about 14,005 units every 63 days since 2006. As of 2 December 2016 he still owns at least 2,500 units of Spero Therapeutics Inc stock.
You can see the complete history of Milind Deshpande stock trades at the bottom of the page.
Dr. Milind S. Deshpande Ph.D. serves as Independent Chairman of the Board of the Company. Deshpande is currently the President and Chief Executive Officer at Nayan Therapeutics, where he has served since February 2019. He is also a Venture Partner at RA Capital, where he has served since October 2018. Dr. Deshpande joined Achillion Pharmaceuticals, Inc. in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004 and Executive Vice President of Research and Chief Scientific Officer in June 2007. He was promoted to President of Research and Development in October 2010. In May 2013, Dr. Deshpande was appointed President and Chief Executive Officer of Achillion and joined its board of directors on which he served until May 2018. Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb Co. from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India. Deshpande is qualified to serve on our Board of Directors due to his extensive experience in the life sciences industry.
As the Independent Chairman of the Board of Spero Therapeutics Inc, the total compensation of Milind Deshpande at Spero Therapeutics Inc is $122,874. There are 8 executives at Spero Therapeutics Inc getting paid more, with Ankit Mahadevia having the highest compensation of $1,785,680.
Milind Deshpande is 63, he's been the Independent Chairman of the Board of Spero Therapeutics Inc since 2014. There are 5 older and 13 younger executives at Spero Therapeutics Inc. The oldest executive at Spero Therapeutics Inc is Dr. David A. Melnick M.D., 69, who is the Chief Medical Officer.
Milind's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 15 years, insiders at Spero Therapeutics Inc have traded over $15,920,732 worth of Spero Therapeutics Inc stock and bought 3,223,281 units worth $44,767,755 . The most active insiders traders include Plc Gsk, Jean Francois Formela, and Capital Management, Llc Aqu.... On average, Spero Therapeutics Inc executives and independent directors trade stock every 71 days with the average trade being worth of $122,858. The most recent stock trade was executed by Ankit Mahadevia on 27 August 2024, trading 5,912 units of SPRO stock currently worth $7,981.
spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.
Spero Therapeutics Inc executives and other stock owners filed with the SEC include: